Cargando…

Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis

Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss of tumor suppressors RB1, TP53, and PTEN are frequent in NEPC but also present in a subset...

Descripción completa

Detalles Bibliográficos
Autores principales:	Conteduca, Vincenza, Ku, Sheng-Yu, Fernandez, Luisa, Dago-Rodriquez, Angel, Lee, Jerry, Jendrisak, Adam, Slade, Megan, Gilbertson, Cole, Manohar, Jyothi, Sigouros, Michael, Wang, Yipeng, Dittamore, Ryan, Wenstrup, Rick, Mosquera, Juan Miguel, Schonhoft, Joseph D., Beltran, Himisha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361159/ https://www.ncbi.nlm.nih.gov/pubmed/34385567 http://dx.doi.org/10.1038/s41698-021-00211-1

Ejemplares similares

Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Epigenetics in prostate cancer: clinical implications
por: Conteduca, Vincenza, et al.
Publicado: (2021)

The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression
por: Terry, Stéphane, et al.
Publicado: (2014)

Evolution of structural rearrangements in prostate cancer intracranial metastases
por: Khani, Francesca, et al.
Publicado: (2023)

Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases
por: Khani, Francesca, et al.
Publicado: (2023)

Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis
por: Greene, Stephanie B., et al.
Publicado: (2016)

Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer
por: Brady, Nicholas J., et al.
Publicado: (2021)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay
por: Orlando, Francesco, et al.
Publicado: (2022)

Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology
por: Beg, Shaham, et al.
Publicado: (2020)

DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms
por: Yao, James, et al.
Publicado: (2022)

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
por: Anantharaman, Archana, et al.
Publicado: (2016)

Divergent clonal evolution of castration resistant neuroendocrine prostate cancer
por: Beltran, Himisha, et al.
Publicado: (2016)

Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer
por: Lu, David, et al.
Publicado: (2020)

Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma
por: Musselman, Kelsey, et al.
Publicado: (2019)

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Functional comparison of exome capture-based methods for transcriptomic profiling of formalin-fixed paraffin-embedded tumors
por: Shohdy, Kyrillus S., et al.
Publicado: (2021)

Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab
por: Alnajar, Hussein, et al.
Publicado: (2022)

Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care
por: Rennert, Hanna, et al.
Publicado: (2016)

Primary neuroendocrine carcinoma of the thymus
por: Gaude, Gajanan S., et al.
Publicado: (2013)

Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer
por: Tiwari, Ritika, et al.
Publicado: (2020)

Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine
por: Simbolo, Michele, et al.
Publicado: (2018)

Hepatitis C Virus Infection and Mixed Cryoglobulinemia
por: Lauletta, Gianfranco, et al.
Publicado: (2012)

Neuroendocrine Carcinoma of the Kidney and Bladder with Loss of Heterozygosity and Changes in Chromosome 3 Copy Number
por: Okada, Atsushi, et al.
Publicado: (2015)

Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth
por: Gritsina, Galina, et al.
Publicado: (2023)

Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment
por: Sternberg, Cora N., et al.
Publicado: (2022)

The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
por: Van Emmenis, Lucie, et al.
Publicado: (2023)

Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel
por: Gurioli, Giorgia, et al.
Publicado: (2022)

Primary Squamous Cell Carcinoma of the Urinary Bladder Presenting as Peritoneal Carcinomatosis
por: Beltran, Himisha, et al.
Publicado: (2010)

Timing Facilitated Site Transfer of an Enzyme on DNA
por: Schonhoft, Joseph D., et al.
Publicado: (2012)

Small extracellular vesicles modulated by αVβ3 integrin induce neuroendocrine differentiation in recipient cancer cells
por: Quaglia, Fabio, et al.
Publicado: (2020)

Copy number alterations in small intestinal neuroendocrine tumors determined by array comparative genomic hybridization
por: Hashemi, Jamileh, et al.
Publicado: (2013)

Loss of copy of MIR1-2 increases CDK4 expression in ileal neuroendocrine tumors
por: Contractor, Tanupriya, et al.
Publicado: (2020)

Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage
por: Gjyrezi, Ada, et al.
Publicado: (2021)

RepB C-terminus mutation of a pRi-repABC binary vector affects plasmid copy number in Agrobacterium and transgene copy number in plants
por: Vaghchhipawala, Zarir, et al.
Publicado: (2018)

Imaging of Pancreatic Neuroendocrine Neoplasms
por: Chiti, Giuditta, et al.
Publicado: (2021)

Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test
por: González-Billalabeitia, Enrique, et al.
Publicado: (2018)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

ODP020 A Challenging Case of Poorly Differentiated Carcinoma with Neuroendocrine Differentiation and Adrenal Mass
por: Mosquera, Jorge, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r1n2r0b4f0m0cu8fisvpo8rong